Terpenoids from Curcumae Rhizoma: Their anticancer effects and clinical uses on combination and versus drug therapies - 16/04/21
, Wan Liao a, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 31 |
| Iconographies | 6 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Cancer is a fatal disease with high mortality and low survival rate worldwide. At present, there is still no known cure for most cancers. Traditional Chinese medicine (TCM) represents a noteworthy reservoir for anticancer agents in drug discovery and development. Curcumae Rhizoma (called Ezhu in Chinese) is widely prescribed in TCM for anticancer therapy owing to its broad-spectrum antineoplastic activities. Especially, the terpenoids isolated from the essential oil of Curcumae Rhizoma form an integral part of cancer research and are well established as a potential anticancer agent. For example, β-elemene has been developed into a new drug for the treatment of solid tumors in China, and is currently undergoing clinical trials in the United States. The review aims to systematically summarize the recent advances on the anticancer effects and related molecular mechanisms of Curcumae Rhizoma, and its terpenoids (β-elemene, Furanodiene, Furanodienone, Germacrone, Curcumol, Curdione). In addition, we evaluated and compared the anticancer efficacy and clinical use of the terpenoids with combination therapies and traditional therapies. Therefore, this review provides sufficient evidence for the anticancer therapeutic potential of Curcumae Rhizoma and its terpenoids, and will contribute to the development of potential anticancer drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abbreviation : 5-Fu, ABC, ABCC3, ABCG2, ABCG2, AIF, Akt, AMPKa, AP-1, ATF, Atg, ATG-5, ATM, Bad, Bad, Bax, Bcl-2, Bcl-xL, BCRP, Bim, BIP, BRAF, Cbl, Cbl-b, CCCP, CDKL3, CD133, Cdc2, Cdc25C, CDKN2B-AS1, Chk2, CHOP, Cox-2, CREB1, CSPG4, CXCR4, DMSO, DNMT1, ECM, eEF1A1, EGFR, EMT, Endo G, EpCAM, Era, ERCC-1, ERE, ERK1/2, ERK1, ERs, ESR1, EZH2, FAK, FBS, FGF-2, FGFR, FOXO3a, FTH1, GADD45, GFAP, GMFβ, GPR124, GPX4, Grp78, GSK3β, HDACs, HER2, Hes1, HIF1A, HIF-1α, HLA-I, HPV, Hsp90, hTERT, HULC, IDH1, IGF-1R, IGFBP1, IRE1a, JAK, JNK, KRAS, LDH, MAPK, MDR, MKK, MMP, MRP, Mta-1, MTA3, mTOR, NF-κB, NOS, PAK1I, PARP, PCNA, PD-L1, PERK, P-gp, PI3K, PC, PPARγ, pRb, pRB1, PTEN, PUMA, Raf-1, Ras, ROS, SCID, SHH, SIP1, SLC7A11, Smad, SNAI1, SNAI2, Sp1, Stat, STAT3, TAP1, TAP2, TGF-β, TNFR1, TNF-α, TOPO I, TOPO IIα, TP53, TPA, uPA, uPAR, VDR, VEGF, VEGFA, WT1, XIAP, α-PD-L1, ΔΨm
Keywords : Curcumae Rhizoma, Anti-cancer, β-elemene, Curcumol, Furanodiene, Terpenoids
Plan
Vol 138
Article 111350- juin 2021 Retour au numéro
Article précédent
- Stem cell-based approaches in cardiac tissue engineering: controlling the microenvironment for autologous cells
- Robin Augustine, Pan Dan, Anwarul Hasan, Israa Magdi Khalaf, Parvathy Prasad, Kajal Ghosal, Carmine Gentile, Lana McClements, Pablo Maureira
- CXCL8 chemokine in ulcerative colitis
- Yunfei Zhu, Shihua Yang, Nan Zhao, Chuanguo Liu, Fayan Zhang, Yuting Guo, Huimin Liu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?